1-5 of 5
leukemia, secondary acute
Close
Sort by
Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Clinical Trials & Observations
Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, Sawyer Jacobson, Jonathan E. Kolitz, Mohan Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2775–2787.
https://doi.org/10.1182/bloodadvances.2021004233
Published: 2021
Includes: Supplemental data
Journal Articles

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Clinical Trials & Observations
Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes, Jeffrey E. Lancet
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1719–1728.
https://doi.org/10.1182/bloodadvances.2020003510
Published: 2021
Includes: Supplemental data
Journal Articles

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Clinical Trials & Observations
Claude Gardin, Cécile Pautas, Elise Fournier, Raphaël Itzykson, Emilie Lemasle, Jean-Henri Bourhis, Lionel Adès, Jean-Pierre Marolleau, Jean-Valère Malfuson, Lauris Gastaud, Emmanuel Raffoux, Juliette Lambert, Thorsten Braun, Xavier Thomas, Sylvain Chantepie, Thomas Cluzeau, Stéphane de Botton, Céline Berthon, Nicolas Boissel, Nicolas Duployez, Christine Terré, Régis Peffault de Latour, Mauricette Michallet, Karine Celli-Lebras, Claude Preudhomme, Hervé Dombret
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1942–1949.
https://doi.org/10.1182/bloodadvances.2019001349
Published: 2020
Includes: Supplemental data
Journal Articles

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study

Clinical Trials & Observations
Salyka Sengsayadeth, Katie S. Gatwood, Ariane Boumendil, Myriam Labopin, Jürgen Finke, Arnold Ganser, Matthias Stelljes, Gerhard Ehninger, Dietrich Beelen, Dietger Niederwieser, Didier Blaise, Peter Dreger, Ghulam Mufti, Patrice Chevallier, Audrey Mailhol, Maria H. Gilleece, Norbert Gorin, Jordi Esteve, Fabio Ciceri, Frederic Baron, Christoph Schmid, Sebastian Giebel, Mohamad Mohty, Bipin N. Savani, Arnon Nagler
Journal: Blood Advances
Blood Adv (2018) 2 (16): 2127–2135.
https://doi.org/10.1182/bloodadvances.2018019976
Published: 2018
Journal Articles

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Clinical Trials & Observations
Prajwal Boddu, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Elias Jabbour, Gautam Borthakur, Marina Konopleva, Kapil N. Bhalla, Naval Daver, Courtney D. DiNardo, Christopher B. Benton, Koichi Takahashi, Zeev Estrov, Sherry R. Pierce, Michael Andreeff, Jorge E. Cortes, Tapan M. Kadia
Journal: Blood Advances
Blood Adv (2017) 1 (17): 1312–1323.
https://doi.org/10.1182/bloodadvances.2017008227
Published: 2017
Includes: Supplemental data